Nalaganje...
90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity
Y-ibritumomab tiuxetan (90Y-IT) combines the benefits of a monoclonal antibody with the efficacy of radiation in the treatment of B-cell non-Hodgkin lymphoma (NHL), a remarkably radiosensitive hematologic malignancy. 90Y-IT activity has been well established in the indolent setting, being approved i...
Shranjeno v:
| izdano v: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Impact Journals LLC
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4884941/ https://ncbi.nlm.nih.gov/pubmed/26657116 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6531 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|